Jonathan Zalevsky
Chief Research & Development Officer Nektar Therapeutics
Jonathan Zalevsky, PhD, is Chief Research & Development Officer at Nektar Therapeutics, overseeing research, clinical development, regulatory affairs, and biologics process development. Since joining Nektar in 2015, he has driven the growth of its immunology and immuno-oncology pipeline, including early development of rezpegaldesleukin and NKTR-0165. Previously, he was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals and held R&D roles at Xencor, advancing its first four clinical-stage assets. Dr. Zalevsky earned his PhD in Biochemistry from UCSF and dual BS degrees in Biochemistry and Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder.
Seminars
- Exploring the global Treg landscape to identify emerging opportunities and the direction of future Treg development
- Exploring the interest in Treg collaboration and investment amid industry changes and recent changes in the industry
- Discussing the broad landscape of Treg therapy economics considering cost, reimbursement and tariff impacts
- Showcasing the unique mechanism of Nektar’s REZPEG IL-2 platform and why it is effective in modulating immune balance
- Highlighting long-term maintenance data from the REZOLVE-AD study to demonstrate sustained efficacy and patient benefit
- Exploring how REZPEG can redefine therapeutic expectations for chronic atopic dermatitis management
